home / stock / esalf / esalf articles
Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd (OTC:ESALF) (OTC:ESALY) faced a setback as the much-anticipated Oral Explanation...
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pem...
The U.S. Centers for Medicare and Medicaid Services has revised its policy permitting multiple uses of amyloid positron emission tomograp...
Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (...
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) have provided updates on two Phase 3 trials, LEAP-006...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infu...
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the ...